<DOC>
	<DOC>NCT01099748</DOC>
	<brief_summary>The objective of this study is to estimate the effect of lersivirine on the pharmacokinetics of R-methadone and S-methadone and to investigate the safety and tolerability of lersivirine when co-administered with methadone. Symptoms of methadone withdrawal will also be assessed.</brief_summary>
	<brief_title>Estimate The Effect Of Lersivirine On The Pharmacokinetics Of S- And R-Methadone</brief_title>
	<detailed_description />
	<mesh_term>Methadone</mesh_term>
	<criteria>Healthy male and/or female subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history except drug abuse), full physical examination, including blood pressure and pulse rate measurement, 12lead ECG and clinical laboratory tests). Body Mass Index (BMI) of 17.5 to 35.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Receiving stable methadone maintenance treatment for at least 3 months (dose range 50150 mg QD). Subjects on therapy for Hepatitis B and/or Hepatitis C; Evidence of impaired liver function (ie, AST and/or ALT greater than 3 times the upper limit of normal, total bilirubin &gt;1.5 times the upper limit of normal, albumin &lt;3.5 g/dL). 12lead ECG demonstrating QTc &gt;450 msec for males and QTc &gt;470 msec for females or any other clinically significant abnormalities at screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>lersivirine</keyword>
	<keyword>methadone</keyword>
</DOC>